Ozempic vs. Wegovy: What Actually Differs Between the Two Semaglutide Brands

Ozempic and Wegovy are both brand names for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. They contain the same molecule, but they are approved by the FDA for different indications, come in different maximum doses, and are typically priced differently depending on insurance formularies.

Ozempic is FDA-approved for the treatment of type 2 diabetes, alongside diet and exercise, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease.

Wegovy is FDA-approved for chronic weight management in adults and adolescents (12+) with obesity or overweight plus at least one weight-related condition, and separately for reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.

Ozempic is titrated up to a maintenance dose of 1 mg or 2 mg once weekly. Wegovy is titrated to a higher maintenance dose of 2.4 mg once weekly, reflecting its focus on weight management outcomes.

Any dose changes should be made by a prescribing clinician based on tolerability and response — this article is not a substitute for that guidance.

List price and insurance coverage vary by country, plan, and indication. In the U.S., off-label prescribing of Ozempic for weight loss is common but not guaranteed to be covered by insurance, since the drug's on-label approval is for diabetes. Wegovy coverage depends heavily on individual plan formularies.

Because both drugs have faced supply shortages at various points, availability can differ by pharmacy and region even when a prescription is in hand.

The choice between Ozempic and Wegovy isn't really a consumer choice — it follows from what a clinician is treating and what a patient's insurance will cover. If you're evaluating options, the conversation to have is with a prescriber, using your diagnosis, health history, and coverage as the starting point.